Initial findings show ensovibep to be safe and well tolerated with no significant adverse events Predictable exposure seen post administration, confirming the expected half-life of 2‑3 weeks Global phase 2/3 registrational study planned to initiate in Q2 2021 Zurich-Schlieren, Switzerland, March

Zurich-Schlieren, Switzerland, February 26, 2021.   Molecular Partners AG  (SIX: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today published its audited Financial Results for 2020 and the company’s 2020 Annual Report.

Event:  Leerink 10th Annual Global Healthcare Conference Date/Time:  Thursday, February 25, 8:40 AM – 9:10 AM ET (2:40 PM – 3:10 PM CET)   Event:  Cowen 41st Annual Health Care Conference Date/Time:  Tuesday, March 2, 2021, 10:30 AM – 11:00 AM ET (4:30 PM – 5:00 PM CET)   Event:  H.C.

Research & Development Highlights: Virology: Initiated and rapidly advanced COVID-19 antiviral program into the clinic; secured collaboration with Novartis for co-development of multi-specific candidates MP0420 (ensovibep) and MP0423, including options for global commercialization; terms included

New study shows that Molecular Partners’ tri-specific antiviral DARPin® candidates,  ensovibep ( MP0420) and the Company’s preclinical candidate, MP0423, remain therapeutically active against the known mutations of SARS-CoV-2 including those present in the United Kingdom (UK) and South Africa (SA)

Zurich-Schlieren, Switzerland, January 06, 2021.   Molecular Partners AG  (SIX: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will present at or

First-in-human data from ongoing phase 1 study of MP0310 (AMG 506) demonstrate encouraging biological activity, including successful localized tumor engagement and saturation Data from ongoing phase 1 COVID-19 study show that MP0420 (ensovibep) is well tolerated in first dose cohort Unique

New data from clinical and preclinical oncology programs to be presented Preliminary Phase 1 data from anti-COVID-19 candidate MP0420 (ensovibep) expected Zurich-Schlieren, Switzerland, December 02, 2020.   Molecular Partners AG  (SIX: MOLN), a clinical-stage biotech company that is developing a

Zurich-Schlieren, Switzerland, November 30, 2020.   Molecular Partners AG  (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that Dr. Patrick Amstutz, CEO of Molecular Partners, will participate

Zurich-Schlieren, Switzerland, November 23, 2020.   Molecular Partners AG  (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that a first cohort of eight healthy volunteers has been dosed in a